We are live on ! Find out more
NWBO

Northwest Biotherapeutics
NWBO

Delisted

NWBO was delisted on the 16th of December, 2016.

10 hedge funds and large institutions have $1.69M invested in Northwest Biotherapeutics in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

23% less funds holding

Funds holding: 13 → 10 (-3)

48% less capital inflows, than outflows

Capital inflows: $184K | Capital outflows: $352K

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 3

Holders
10
Holders Change
-3
Holders Change %
-23.08%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

NWBO Hedge Fund Activity: Q2 2023 in Review

10 of the 6,386 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics (NWBO) for Q2 2023, worth a combined $1.69M — down 16% from $2.01M a quarter earlier.

Sellers outnumbered buyers: 3 funds closed out of NWBO and 0 opened new positions — a net loss of 3 holders — while 0 trimmed existing stakes and 2 added.

The largest buyer was Sentinus LLC, adding an estimated $158K. The largest seller was Ancora Advisors, exiting entirely with an estimated $329K sold.

  • 10 institutional investors held Northwest Biotherapeutics (NWBO) as of Q2 2023, down from 13 in Q1 2023.
  • Funds reported $1.69M of Northwest Biotherapeutics stock for Q2 2023, down 16% quarter-over-quarter.
  • 0 funds opened new Northwest Biotherapeutics positions in Q2 2023 and 3 closed out, a net change of -3 holders.
  • The largest Northwest Biotherapeutics buyer in Q2 2023 was Sentinus LLC, an estimated $158K added.
  • The largest Northwest Biotherapeutics seller in Q2 2023 was Ancora Advisors, an estimated $329K sold.

Based on aggregated 13F filings for Q2 2023.